Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ) has issued an announcement.
Beijing Biostar Pharmaceuticals Co., Ltd., a company incorporated in the People’s Republic of China, has received approval from the Grand Court of the Cayman Islands to appoint a receiver over the LFM Stable Income Fund SP. This move is part of the company’s efforts to initiate winding-up petitions and receivership proceedings for the fund, following the court’s recognition of US-Biostar as a creditor. The company plans to keep shareholders and potential investors informed with further announcements as necessary.
More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Average Trading Volume: 230,109
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$715.2M
See more data about 2563 stock on TipRanks’ Stock Analysis page.